214 related articles for article (PubMed ID: 34024854)
21. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
[TBL] [Abstract][Full Text] [Related]
22. Drug-induced liver injury by glecaprevir/pibrentasvir treatment for chronic hepatitis C infection: a systematic review and meta-analysis.
Hung HY; Hung WL; Shih CL; Chen CY
Ann Med; 2022 Dec; 54(1):108-120. PubMed ID: 34969349
[No Abstract] [Full Text] [Related]
23. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C.
Madsen LW; Christensen PB; Fahnøe U; Pedersen MS; Bukh J; Øvrehus A
Liver Int; 2021 Nov; 41(11):2601-2610. PubMed ID: 34154034
[TBL] [Abstract][Full Text] [Related]
24. Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy.
Cotter TG; Jensen DM
Drug Des Devel Ther; 2019; 13():2565-2577. PubMed ID: 31534310
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection.
Lawitz E; Flisiak R; Abunimeh M; Sise ME; Park JY; Kaskas M; Bruchfeld A; Wörns MA; Aglitti A; Zamor PJ; Xue Z; Schnell G; Jalundhwala YJ; Porcalla A; Mensa FJ; Persico M
Liver Int; 2020 May; 40(5):1032-1041. PubMed ID: 31821716
[TBL] [Abstract][Full Text] [Related]
26. High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use: Some issues.
Dai CY; Huang CF; Huang JF; Chuang WL; Yu ML
J Infect; 2022 Oct; 85(4):e94-e95. PubMed ID: 35810942
[No Abstract] [Full Text] [Related]
27. Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all hepatitis C virus infected patients in the real-world experience?
Zarębska-Michaluk D; Jaroszewicz J; Pabjan P; Łapiński TW; Mazur W; Krygier R; Dybowska D; Halota W; Pawłowska M; Janczewska E; Buczyńska I; Simon K; Dobracka B; Citko J; Laurans Ł; Tudrujek-Zdunek M; Tomasiewicz K; Piekarska A; Sitko M; Białkowska-Warzecha J; Klapaczyński J; Sobala-Szczygieł B; Horban A; Berak H; Deroń Z; Lorenc B; Socha Ł; Tronina O; Flisiak R
J Gastroenterol Hepatol; 2021 Jul; 36(7):1944-1952. PubMed ID: 33171526
[TBL] [Abstract][Full Text] [Related]
28. High Real-World Sustained Virologic Response Rate with Glecaprevir/Pibrentasvir at a Racially Diverse Urban Academic Medical Center.
Martin MT; Waring N; Naveed A
Gut Liver; 2022 May; 16(3):489-492. PubMed ID: 35145046
[No Abstract] [Full Text] [Related]
29. [A case of HCV genotype 3b with compensated stage cirrhosis who have two times treatment-experienced with the use of glecaprevir/pibrentasvir combined with sofosbuvir and ribavirin for 16 weeks].
Wang CY; Liu J; Wen J; Ma HX; Li J
Zhonghua Gan Zang Bing Za Zhi; 2021 Dec; 29(12):1194-1195. PubMed ID: 35045636
[TBL] [Abstract][Full Text] [Related]
30. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Berg T; Naumann U; Stoehr A; Sick C; John C; Teuber G; Schiffelholz W; Mauss S; Lohmann K; König B; Pangerl A; Niederau C
Aliment Pharmacol Ther; 2019 Apr; 49(8):1052-1059. PubMed ID: 30874328
[TBL] [Abstract][Full Text] [Related]
31. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
[TBL] [Abstract][Full Text] [Related]
32. Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C-Registry.
Klinker H; Naumann U; Rössle M; Berg T; Bondin M; Lohmann K; Koenig B; Zeuzem S; Cornberg M
Liver Int; 2021 Jul; 41(7):1518-1522. PubMed ID: 33966349
[TBL] [Abstract][Full Text] [Related]
33. Use of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus infection and severe renal impairment.
Yap DYH; Liu KSH; Hsu YC; Wong GLH; Tsai MC; Chen CH; Hsu CS; Hui YT; Li MKK; Liu CH; Kan YM; Yu ML; Yuen MF
Clin Mol Hepatol; 2020 Oct; 26(4):554-561. PubMed ID: 32854457
[TBL] [Abstract][Full Text] [Related]
34. Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
Hara T; Ohara T; Taniguchi M; Sakai H; Oka K; Iwai N; Tsuji T; Okuda T; Nagata A; Komaki T; Sakagami J; Kagawa K
Intern Med; 2021 Aug; 60(15):2437-2443. PubMed ID: 33612683
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
[TBL] [Abstract][Full Text] [Related]
36. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
Huang CF; Kuo HT; Chang TS; Lo CC; Hung CH; Huang CW; Chong LW; Cheng PN; Yeh ML; Peng CY; Cheng CY; Huang JF; Bair MJ; Lin CL; Yang CC; Wang SJ; Hsieh TY; Lee TH; Lee PL; Wu WC; Lin CL; Su WW; Yang SS; Wang CC; Hu JT; Mo LR; Chen CT; Huang YH; Chang CC; Huang CS; Chen GY; Kao CN; Tai CM; Liu CJ; Lee MH; Tsai PC; Dai CY; Kao JH; Lin HC; Chuang WL; Chen CY; Tseng KC; Yu ML
Sci Rep; 2021 Dec; 11(1):23473. PubMed ID: 34873250
[TBL] [Abstract][Full Text] [Related]
37. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).
Wei L; Wang G; Alami NN; Xie W; Heo J; Xie Q; Zhang M; Kim YJ; Lim SG; Fredrick LM; Lu W; Liu W; Kalluri HV; Krishnan P; Tripathi R; Mobashery N; Burroughs M; Asatryan A; Jia J; Hou J
Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):839-849. PubMed ID: 32682494
[TBL] [Abstract][Full Text] [Related]
38. Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials.
Brown A; Welzel TM; Conway B; Negro F; Bräu N; Grebely J; Puoti M; Aghemo A; Kleine H; Pugatch D; Mensa FJ; Chen YJ; Lei Y; Lawitz E; Asselah T
Liver Int; 2020 Apr; 40(4):778-786. PubMed ID: 31568620
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.
Asselah T; Kowdley KV; Zadeikis N; Wang S; Hassanein T; Horsmans Y; Colombo M; Calinas F; Aguilar H; de Ledinghen V; Mantry PS; Hezode C; Marinho RT; Agarwal K; Nevens F; Elkhashab M; Kort J; Liu R; Ng TI; Krishnan P; Lin CW; Mensa FJ
Clin Gastroenterol Hepatol; 2018 Mar; 16(3):417-426. PubMed ID: 28951228
[TBL] [Abstract][Full Text] [Related]
40. [Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].
Sánchez Suárez MM; Martín Roldán A; Cantudo Cuenca MR
Rev Esp Quimioter; 2024 Jun; 37(3):283-284. PubMed ID: 38638059
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
